Ann Arbor, Michigan, biopharmaceutical company Cerenis Therapeutics added $13.9 million to a July investment round that it will use to continue clinical trials of a drug to treat heart disease. Cerenis will use its latest investment to do Phase II clinical trial development of CER-001, which mimics high-density lipid ("good") cholesterol and can rapidly reverse atherosclerotic plaque.
Cerenis Therapeutics has pulled in a $51.7 million Series C round to fund Phase 2 trials of a drug that treats cardiovascular disease. The company, with operations in France and Ann Arbor, Michigan, has now raised $138 million in venture funding since its 2005 inception, according to a statement. (The company listed its funding amounts […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.